Compare Amvis Holdings, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 33,525 Million (Small Cap)
12.00
NA
0.00%
0.55
9.02%
0.88
Revenue and Profits:
Net Sales:
12,664 Million
(Quarterly Results - Mar 2026)
Net Profit:
815 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.52%
0%
-22.52%
6 Months
-29.98%
0%
-29.98%
1 Year
-34.96%
0%
-34.96%
2 Years
-86.22%
0%
-86.22%
3 Years
-89.89%
0%
-89.89%
4 Years
-91.37%
0%
-91.37%
5 Years
-94.85%
0%
-94.85%
Amvis Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
37.14%
EBIT Growth (5y)
24.12%
EBIT to Interest (avg)
27.26
Debt to EBITDA (avg)
0.98
Net Debt to Equity (avg)
0.54
Sales to Capital Employed (avg)
0.73
Tax Ratio
29.49%
Dividend Payout Ratio
10.66%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.46%
ROE (avg)
21.90%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.24
EV to EBIT
11.16
EV to EBITDA
7.52
EV to Capital Employed
1.15
EV to Sales
1.35
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
10.31%
ROE (Latest)
10.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
12,664.00
12,047.00
5.12%
Operating Profit (PBDIT) excl Other Income
2,017.00
2,383.00
-15.36%
Interest
181.00
138.00
31.16%
Exceptional Items
34.00
0.00
Consolidate Net Profit
815.00
1,342.00
-39.27%
Operating Profit Margin (Excl OI)
95.20%
143.80%
-4.86%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 5.12% vs 19.80% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -39.27% vs -32.15% in Mar 2025
Annual Results Snapshot (Consolidated) - Sep'25
Sep'25
Sep'24
Change(%)
Net Sales
49,174.00
42,475.00
15.77%
Operating Profit (PBDIT) excl Other Income
8,935.00
12,462.00
-28.30%
Interest
563.00
359.00
56.82%
Exceptional Items
-657.00
0.00
Consolidate Net Profit
3,660.00
7,438.00
-50.79%
Operating Profit Margin (Excl OI)
125.40%
249.70%
-12.43%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2025 is 15.77% vs 32.80% in Sep 2024
Consolidated Net Profit
YoY Growth in year ended Sep 2025 is -50.79% vs 17.88% in Sep 2024
About Amvis Holdings, Inc. 
Amvis Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






